Category: 135034-10-5

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135034-10-5,3-Chloro-6-iodopyridazine,as a common compound, the synthetic route is as follows.

Procedure E: General Procedure of Negishi Coupling; A bromopyridine solution (1.6 eq.) in the freshly distilled and degassed THF is cooled to -78 C. in a three-neck round-bottom flask fitted with a condenser. The butyllithium (2.5 M in hexane, 1.6 eq.) is added gently and the reaction medium is stirred for 30 minutes at -78 C. The zinc chloride solution (previously sublimated, 1.6 eq.) in the degassed THF is cannulated at -78 C. into the reaction medium. The solution is stirred at room temperature for 30 minutes, then a solution of tetrakis(triphenylphosphine) palladium (0) (0.1 eq.) and halopyridazine (1 eq.) in the THF is cannulated into the reaction medium. The solution is stirred for 48 hours at a temperature that depends on the substrate. The medium is treated with a NaHCO3 saturated solution. The solution is filtered through Celite and sequentially washed with DCM and with concentrated ammonia (25 N). The organic phase is dried over Na2SO4 and concentrated under reduced pressure.; Route 3:; This synthetic route uses the Negishi coupling of an organozinc derivative with a halogenated pyridazine. The zinc pyridine is formed in situ from 2-bromopyridine in the presence of butyllithium and zinc chloride. A solution of 3-chloro-6-iodopyridazine (103) and tetrakis(triphenylphosphine) palladium (0) is then cannulated to give a compound (8a) with a yield of 62% (initial step). Bipyridazine (19) is achieved through homocoupling., 135034-10-5

As the paragraph descriping shows that 135034-10-5 is playing an increasingly important role.

Reference£º
Patent; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.; US2010/4443; (2010); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

135034-10-5, 3-Chloro-6-iodopyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2,6-Dichloro-4-(6-(ethyl(3-fluorobenzyl)amino)pyridazin-3-yl)phenol (compound 127) 3-Chloro-6-iodopyridazine (prepared as described by Goodman et al. Tetrahedron 1999, 55, 15067-15070) (100 mg, 0.42 mmol) and N-(3-fluorobenzyl)ethanamine (127 mg, 0.83 mmol) were heated in dimethylacetamide (2 mL) at 100 C. for 6 d. EtOAc (10 mL) and 1 M HCl (aqueous, 5 mL) were added and the layers were separated. The aqueous layer was extracted with EtOAc and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo leaving a brown oil (103 mg) which was used in the next step without further purification. (Note: A mixture of mono-displaced products, the iodo-displaced and the chloro-displaced compounds, were obtained at this point). The residue was dissolved in dioxan (2 mL) and PdCl2(dppf) (8 mg, 0.0095 mmol), tert-butyl(2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)dimethylsilane (83 mg, 0.21 mmol) and 1.5 M Na2CO3 solution (aqueous, 1 mL) were added. The dark mixture was heated in a sealed tube at 80 C. for 1 d. EtOAc and H2O were added and the layers separated. The aqueous layer was extracted with EtOAc and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by preparative HPLC to afford (19.9 mg, 0.051 mmol, 12%) of the title compound. 1H NMR delta (ppm) (DMSO-d6): 1.18 (3H, t, J=6.92 Hz), 3.71 (2H, q, J=6.98 Hz), 4.92 (2H, s), 7.07-7.16 (4H, m), 7.37-7.45 (1H, m), 7.96 (1H, d, J=9.64 Hz), 8.03 (2H, s). LCMS (10 cm_esi_formic) tR 3.48 min; m/z 390 [M-H]-., 135034-10-5

As the paragraph descriping shows that 135034-10-5 is playing an increasingly important role.

Reference£º
Patent; Institute for OneWorld Health; US2009/270398; (2009); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135034-10-5,3-Chloro-6-iodopyridazine,as a common compound, the synthetic route is as follows.

To a stirred solution of Intermediate 2 (0.25 g, 0.8 mmol) in dry DMF (5 mL), TEA (0.36 ml,2.85 mmol) and 3-chloro-6-iodopyridazine (0.123 g, 0.99 mmol) were added at rt and the reaction mixture was stirred at 90 C overnight. The resulting reaction mixture was cooled to rt and DMF was evaporated under reduced pressure. To the resulting crude mixture, water (20 mL) was added and the product was extracted with EtOAc (2 x 30 mL). Theresulting organic layer was dried over Na2SO4 and concentrated. This crude product waspurified by flash column chromatography to afford the title compound ( off white solid). 1HNMR (400 MHz, CDCI3): 68.86-8.84 (m, 2H), 8.11 (d, J = 8.8 Hz, IH), 8.03 (d, J = 2.0 Hz,I H), 7.90 (dd, J = 8.8, 2.0 Hz, I H), 7.45 (d, J = 9.6 Hz, I H), 6.60 (d, J = 9.6 Hz, I H), 3.65-3.58 (m, 5H), 2.73-2.67 (m, 2H), 2.59-2.54 (m, 2H), 1.51 (d, J = 6.8 Hz, 3H). LCMS:(Method A) 447.0 (M +H), Rt. 2.13 mm, 99.59% (Max). HPLC: (Method A) Rt. 2.16 mm,98.99% (Max).

135034-10-5, As the paragraph descriping shows that 135034-10-5 is playing an increasingly important role.

Reference£º
Patent; ASCENEURON S. A.; QUATTROPANI, Anna; KULKARNI, Santosh, S.; GIRI, Awadut, Gajendra; (280 pag.)WO2017/144633; (2017); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

135034-10-5, 3-Chloro-6-iodopyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1. 2.93 g (9.09 mmol) of 1-[2-(tetrahydropyran-2-yloxy)ethyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (prepared by reaction of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 2-(2-bromoethoxy)tetrahydropyran with caesium carbonate in acetonitrile) and 4.25 g (20.0 mmol) of tripotassium phosphate trihydrate are added to a solution of 2.40 g (10.0 mmol) of 3-chloro-6-iodopyridazine in 12 ml of 1,2-dimethoxyethane. The resultant suspension is heated to 80 C. under nitrogen and with stirring, and 210 mg (0.30 mmol) of bis(triphenylphosphine)-palladium(II) chloride are added. The reaction mixture is stirred at 80 C. for 18 hours. The mixture is allowed to cool to room temperature, and 60 ml of water and 30 ml of dichloromethane are added. The organic phase is separated off, washed with water, dried over sodium sulfate and evaporated: 3-chloro-6-{1-[2-(tetrahydropyran-2-yloxy)ethyl]-1H-pyrazol-4-yl}pyridazine as brown wax-like solid ; ESI 309.

135034-10-5, 135034-10-5 3-Chloro-6-iodopyridazine 15418839, apyridazine compound, is more and more widely used in various fields.

Reference£º
Patent; MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG; US2011/92498; (2011); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135034-10-5,3-Chloro-6-iodopyridazine,as a common compound, the synthetic route is as follows.

b) Ethyl (?)-3-(3-Chloro-6-pyridazinyl)-2-propenoate.; A suspension of 3- chloro-6-iodopyridazine (2.4 g, 10 mmol), ethyl acrylate (4.4 mL, 40 mmol), palladium(II) acetate (90 mg, 0.40 mmol) and tri(o-tolyl)phosphine (366 mg, 1.20 mmol) in DMF (10 mL) and diisopropylethyl amine (5 mL) was stirred with heating (1 1 1 C oil-bath) for 3.5 h, cooled to room temperature, diluted with H20 (50 mL) and extracted with EtOAc (300 mL). The extract was washed (brine) and dried. After solvent removal at reduced pressure, the residue was chromatographed (14% to 20% EtOAc/hexane) to give 174 mg (8%) of ethyl (E)-3- (3-chloro-6-pyridazinyl)-2-propenoate as a brown solid, mp 106-1 10 C. IR 2928, 1715, 1 186 cm”1; 1H NMR (CDC13) delta 1.38 (t, J= 7.5 Hz, 3H, CH2G?), 4.33 (q, J= 7.5 Hz, 2H, CH2CH3), 7.98 (d, J = 16.2 Hz, 1H, CH=CHCO), 7.57 (d, J= 8.4 Hz, 1H, 4-ArH), 7.63 (d, J = 8.4 Hz, 1H, 5-ArH), 7.86 ppm (d, J= 16.2 Hz, 1H, CH=CHCO). HRMS calcdC9H9C1N202 [M + H]+ 213.0425, found 213.0431., 135034-10-5

As the paragraph descriping shows that 135034-10-5 is playing an increasingly important role.

Reference£º
Patent; WAYNE STATE UNIVERSITY; SANDFORD-BURNHAM MEDICAL RESEARCH INSTITUTE; FONTANA, Joseph, A.; DAWSON, Marcia; XIA, Zebin; WO2011/79305; (2011); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135034-10-5,3-Chloro-6-iodopyridazine,as a common compound, the synthetic route is as follows.

Step 5: 3-chloro-6-(1-methyl-1/-/-pyrazol-4-yl)pyridazineWater (253 mL) and THF (842 mL) were put in the reaction balloon. The reagents were added one by one to the stirred reaction mixture: potassium phosphate monohydrate 86,2 g (374 mmol) and BTEAC 2,25g (9,88 mmol). Then 3-chloro-6-iodopyhdazine, 45 g (187,2 mmol) and 1-methyl-4-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 H-pyrazole, 46,73g(224,6 mmol) were added and finally triphenylphosphine, 1 ,96g (7,49 mmol) and palladiumdiacetate, 420 mg (1 ,87 mmol) were added. The reaction mixture was heated at 65C for 16h . The reaction mixture was allowed to cool to 600C. Then 935 mL water and301 , 5g sodium chloride were added. The mixture was stirred for 15 minutes and allowed to cool to 450C. The phases were separated and the organic layer was washed with a solution of 45 g sodium chloride in 374 mL water. The organic layer was separated and stirred with magnesium sulphate (225 g) and charcoal (4,5 g). The mixture was filtered and evaporated. The evaporation residue was co-evaporated with toluene twice and evaporated further till a final volume of 200 ml. This residue was stirred for 16 h at room temperature. The resulting solids were collected by filtration. The solids were dried at reduced pressure affording 29,7 g of the title compound (152,6 mmol, yield 82%).1 H NMR (600 MHz, CHLOROFORM-c/) delta ppm 4.00 (s, 3 H) 7.46 (d, J=8.69 Hz, 1 H) 7.56 (d, J=9.06 Hz, 1 H) 7.98 (s, 1 H) 8.11 (s, 1 H), 135034-10-5

135034-10-5 3-Chloro-6-iodopyridazine 15418839, apyridazine compound, is more and more widely used in various.

Reference£º
Patent; JANSSEN PHARMACEUTICA NV; WO2008/155378; (2008); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem